We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




New Spinal Treatment Shows Promise

By HospiMedica staff writers
Posted on 23 Jun 2004
A study has found that injecting a patient's own immune cells into a damaged spinal cord enabled some patients with spinal cord injury to recover a degree of sensation and movement.

In the study, involving 10 patients, immune cells were extracted from each patient's blood, "activated” by incubating them with skin cells, and then injected directly into the damaged spinal cord. More...
This all must be done within 14 days of the injury, so even if larger trials confirm its benefits, the method will not help all the people with existing injuries. The 10 patients were all in the most severe category of spinal injury, called ASIA-A, defined as having no sensation or ability to move below the site of injury.

Three of the patients treated so far have recovered some weak muscle function and are now classed as ASIA-C. One has regained bladder control, while another can stand and walk with assistance. Fewer than 4% of patients normally recover from ASIA-A to C. Two other patients have regained some sensation and are now classed as ASIA-B. Four other patients show signs that nerve signals can pass through the injury site. There were no signs of any ill effects.

The controversial technique is being developed by ProNeuron Biotechnologies (Los Angeles, CA, USA; www.proneuron.com). It is based on the work of Michal Schwarz, of the Weizmann Institute of Science (Rehovet, Israel). Her theory is that one of the reasons for the poor healing of spinal injuries is that the central nervous system is partly isolated from the immune system. It takes months for macrophages, which clean up damaged tissue and promote healing by releasing growth factors, to accumulate at a spinal injury site. However, many researchers remain unconvinced, and some doctors think the new treatment might actually make things worse for patients with spinal injury.

"Whether macrophages are damaging or beneficial is very controversial,” noted Geoff Raisman, who works on spinal cord injury at the National Institute for Medical Research in London (UK).




Related Links:
ProNeuron Biotechnologies

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Electric Bed
DIXION Intensive Care Bed
Open Stapler
PROXIMATE Linear Cutter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.